#Graft Versus Host Disease Market Insight

[deshpandeisha]

Understanding Chronic Graft-versus-Host Disease: Causes, Symptoms, and Diagnosis

The global Chronic Graft-versus-Host Disease (cGvHD) market size reached USD 3.5 Billion in 2021 and is expected to register a revenue CAGR of 13.3% during the forecast period, according to the latest analysis by Emergen Research. Increasing number of allogenic transplants such as bone marrow transplants, rising regulatory approvals for the treatment of Graft Versus Host Disease (GvHD) as well as increase in prevalence of nephrological leukemia, myeloma, and other forms of cancer are some of the key factors driving revenue growth of the chronic graft-versus-host disease market.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1640

Competitive Terrain:

The global Chronic Graft versus Host Disease industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Merck KGaA, Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc., F. Hoffman-La Roche Ltd, Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, and Takeda Pharmaceutical Company Limited

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Chronic Graft versus Host Disease market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Chronic Graft versus Host Disease market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Chronic Graft versus Host Disease market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1640

Market Segmentations of the Chronic Graft versus Host Disease Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Chronic Graft versus Host Disease market on the basis of product, application, and region:

Segments Covered in this report are:

Treatment Type Outlook (Revenue, USD Billion; 2019-2030)

Corticosteroids

mTOR inhibitors

Tyrosine Kinase Inhibitors (TKIs)

Monoclonal Antibodies

Photopheresis light treatment (ECP)

Others

Distribution Channel Outlook (Revenue, USD Billion; 2019-2030)

Hospitals Pharmacies

Retail Pharmacies

Online Pharmacies

Regional Outlook (Revenue, USD Billion; 2019-2030)

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

U.A.E.

South Africa

Turkey

Rest of MEA

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/chronic-graft-versus-host-disease-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1640

[colinwilson11]

Exosome Therapeutics Market Will Grow At Highest Pace Owing To Increasing R&D Investments

Exosome therapeutics involves isolation and characterization of exosomes from various sources like mesenchymal stem cells, immune cells etc and its use in regenerative and immune modulating therapies. Exosomes are being explored as potential delivery vehicles for drugs, genes and other biomolecules owing to their ability to deliver their cargo to specific target sites via surface ligands.

The Exosome Therapeutics Market is estimated to be valued at US$ 32.1 Mn in 2024 and is expected to exhibit a CAGR of 41% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the exosome therapeutics are Aegle Therapeutics,Coya Therapeutics,Evox Therapeutics,Nano 24,ReNeuron. Major players are actively investing in R&D to develop exosome-based treatments for various disease indications such as cancer, neurological disorders. Growing research interest in exploring exosome’s potential role in intercellular communication and biomarker discovery is fueling the demand. Advancements in isolation and characterization methods are enabling better understanding of exosome content and functional impact which is crucial for development of exosome-based clinical applications.

Market Trends

Two major trends driving the exosome therapeutics market are development of exosome isolation techniques and use of mesenchymal stem cell derived exosomes. Significant improvements have been made in development of efficient exosome isolation methods such as ultracentrifugation, size-exclusion chromatography, precipitation, and filtration. These techniques enable high yield and purity isolation which is critical for clinical and research applications. Mesenchymal stem cell derived exosomes possess immuno-regulatory and regenerative properties and are being explored for treatment of conditions such as graft versus host disease, myocardial infarction, lung fibrosis among others.

Market Opportunities

One of the key opportunities is potential use of exosomes as drug delivery vehicles. Exosomes have emerged as attractive drug delivery system due to their natural composition, ability to cross biological barriers and selectively target cells via surface ligands. Exosomes loaded with drugs, proteins or nucleic acids offers safer and more targeted delivery compared to other nanocarriers. Developing exosome-based diagnostics represents another major opportunity. Exosome content profiling can provide valuable insights into various disease states and help develop non-invasive liquid biopsy tests. Significant funding from government and private players is helping advance the promising field of exosome therapeutics.

Impact Of COVID-19 On Exosome Therapeutics Market Growth

The outbreak of COVID-19 pandemic has adversely impacted the growth of exosome therapeutics market globally. Major reasons being restrictions on research activities, disruptions in supply chain and delay in new product launches. During pre-COVID times, the market was growing at a steady pace due to ongoing clinical trials and discovery of new exosome-based therapeutics for various diseases like cancer, diabetes etc. However, post COVID, the market experienced slowdown initially in 2020 due to lockdowns imposed worldwide. Laboratories conducting R&D activities were temporarily shut down impacting overall progress.

Availability of raw materials from overseas suppliers was also hampered globally affecting manufacturing operations of key players. Various clinical trials involving exosome therapeutics had to be either postponed or conducted virtually. The pandemic resulted in diversion of research focus as well as funds towards developing COVID-19 vaccines and therapeutics. Though challenges persisted in initial months, the market is recovering gradually as restrictions are being lifted. Companies are resuming operations with COVID appropriate measures and accelerating clinical research. Telehealth and remote monitoring is also helping drive clinical trials. Going forward, continued investment in R&D, innovations and strategic collaborations would be crucial for the industry to capitalize on the potential of exosome therapeutics.

Geographical Regions With Highest Concentration Of Exosome Therapeutics Market

In terms of value, North America region holds the major share of global exosome therapeutics market, accounting for over 40% share. Presence of top players, ongoing clinical research and availability of latest technologies/infrastructure are driving the market in the region. Within North America, United States represents the largest and fastest growing market. Europe is another lucrative region occupying around 30% share backed by increasing government funding for exosome research. Other emerging regions like Asia Pacific and Latin America are also witnessing rising focus by players to tap growth opportunities.

Fastest Growing Region In Exosome Therapeutics Market

Asia Pacific region is poised to register fastest growth in the Exosome Therapeutics Market during the forecast period. Factors such as rising healthcare expenditure, growing biotech industry, increasing collaborations between foreign players and regional research centers and expanding patient pool are fueling the market growth. Within Asia, China and India have emerged as most promising markets due to presence of skilled labor force and low-cost manufacturing advantages. Moreover, favorable regulatory framework by governments to promote local companies is attracting foreign investments in the region's exosome therapeutics domain.

Get more insights on this topic: https://www.pressreleasebulletin.com/exosome-therapeutics-market-is-estimated-to-witness-high-growth-owing-to-application-in-advanced-cell-free-therapies/

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

What Are The Key Data Covered In This Exosome Therapeutics Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Exosome Therapeutics Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Exosome Therapeutics Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Exosome Therapeutics Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Exosome Therapeutics Market vendors

FAQ’s

Q.1 What are the main factors influencing the Exosome Therapeutics Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Exosome Therapeutics Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Exosome Therapeutics Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[wissenresearchllc]

𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: Graft-Versus-Host Disease (GvHD): Graft-Versus-Host Disease (GvHD)

Wissen Research presents a comprehensive report on Graft-Versus-Host Disease (GvHD) highlighting:

#Market Insight #Opportunity Analysis #Key Opinion Leader Analysis #Regulatory Analysis #Clinical Trial #Product Analysis (Approved and Pipeline) #Patent Analysis #Scientific Literature Analysis #Market Forecast

📑For detailed report: https://www.wissenresearch.com/graft-versus-host-disease-market-report-2023/ 📑 Request customized study: https://www.wissenresearch.com/ask-for-customization/

[sanpdr1994]

Graft Versus Host Disease (GvHD) Treatment Market Types Applications Products Share Growth Insights And Forecasts Report 2032

The global Graft Versus Host Disease (GvHD) Treatment Market is expected to secure US$ 5,655.37 Million in 2032 while expanding at a CAGR of 8.3%.

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors.

Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.

It is tough to diagnose who might develop GvHD after a transplant. Mild form of GvHD is observed in few cases. While in certain cases GvHD may be fatal. GvHD do not occur when recipient receives their own cells through autologous transplant. Prior to a transplant, cells from possible donors are screened to realize how strictly they match the recipient. Chances of GvHD are reduced, or symptoms will be milder, when the match is close.

There are two forms of GvHD:

Acute graft versus host disease (aGvHD).

Chronic graft versus host disease (cGvHD).

Graft Versus Host Disease (GvHD) Treatment Market: Drivers and Restraints

Presently, graft versus host disease (GvHD) market is driven by increase in number of incidence and prevalence of cancer patients which are treated by chemotherapy treatment. Graft versus host disease (GvHD) global market is also fueled by increase in number of bone marrow transplants been carried around the globe to treat specific types of cancers.

Increase in allogeneic hematopoietic stem cell transplant will play key role in global market for graft versus host disease (GvHD). However, cost linked with recent clinical trials and authorizations would acts as a major restraint for graft versus host disease (GvHD) global market.

Graft versus Host Disease (GvHD) Treatment Market: Overview

The global market graft versus host disease (GvHD) treatment is expected to register a healthy CAGR during the forecast period. Innovative development of novel technologies, and increase in the number of cancer patients seeking for chemotherapy treatment is expected to drive the growth of graft versus host disease (GvHD) treatment market in the forecast period (2016-2026).

Graft versus Host Disease (GvHD) Treatment Market: Key Players

Some of the key participating global players in graft versus host disease (GvHD) treatment global market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., Mesoblast Ltd and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

Key Segments Profiled In The Global Graft Versus Host Disease (Gvhd) Treatment Market

Graft Versus Host Disease (GvHD) Treatment Market by Product:

Monoclonal antibodies Graft Versus Host Disease (GvHD) Treatment

mTOR inhibitors Graft Versus Host Disease (GvHD) Treatment

Tyrosine kinase inhibitors Graft Versus Host Disease (GvHD) Treatment

Thalidomide Graft Versus Host Disease (GvHD) Treatment

Etanercept Graft Versus Host Disease (GvHD) Treatment

Graft Versus Host Disease (GvHD) Treatment Market by Disease:

Acute Graft Versus Host Disease (a(GvHD))

Chronic Graft Versus Host Disease (c(GvHD))

Graft Versus Host Disease (GvHD) Treatment Market by Region:

North America Graft Versus Host Disease (GvHD) Treatment Market

Latin America Graft Versus Host Disease (GvHD) Treatment Market

Europe Graft Versus Host Disease (GvHD) Treatment Market

Asia Pacific Graft Versus Host Disease (GvHD) Treatment Market

Middle East & Africa Graft Versus Host Disease (GvHD) Treatment Market

[deepadelve]

Graft Versus Host Disease Market

Graft versus host disease (GvHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when a particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

DelveInsight's "Graft versus host disease (GVHD) Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Graft versus host disease (GVHD), historical and forecasted epidemiology as well as the Graft versus host disease (GVHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of the Graft versus host disease Market report:

The GvHD market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 15.9%.

In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting increase in cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.

GvHD is categorized into two types: aGvHD and cGvHD.

In 2020, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854. In the 7MM, the aGvHD and cGvHD cases are expected to rise to by 2030 during the forecast period, i.e., 2021–2030.

Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,984 in 2020.

In the event of GvHD, corticosteroids are the first line of treatment; however, secondary data demonstrate that up to 40%-60% of all patients will be refractory to steroids. As per DelveInsight’s analysis, around 3,278 cases of cGvHD treated in first-line in the United States in 2020

The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2020, the 7MM mortality adjusted treated aGvHD patients were 9,951 in first-line.

The key players in GvHD market are:

Imbruvica

Temcell HS

Incyte Corporation

Enlivex Therapeutics

Kiadis Pharma

OncoImmune

And Many Others

GvHD has two types Acute GvHD and Chronic GvHD. Acute GvHD is also known as fulminant GVHD, and occurs usually in the initial 2-3 months after transplantation. While Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucous or saliva.

Acute GVHD is staged and graded (grade I-IV) by the number and extent of organ involvement. While Chronic GvHD is staged according to a new clinical scoring system on a four point scale (0-3) with 0 representing no involvement, 1 representing mild involvement (no significant impairment of daily living), 2 representing moderate involvement (significant impairment of daily living) and 3 representing severe impairment (major disability).

“According to Delveinsight, No significant difference was found in incidence of GvHD among male and female”

The launch of the emerging therapies is expected to significantly impact Graft versus host disease (GvHD) treatment scenario in the upcoming years:-

Graft versus host disease therapies covered:

Imbruvica

Temcell HS

Ruxolitinib

Itacitinib

Allocetra

ATIR101

CD24Fc

And Many Others

Table of contents:

Key Insight

Executive Summary of Graft Versus Host Disease (GvHD)

Graft Versus Host Disease (GvHD) Market Overview at a Glance

Disease Background and Overview: Graft Versus Host Disease (GvHD)

Case Reports

Graft Versus Host Disease (GvHD) Epidemiology and Patient Population

United States Epidemiology

EU5 Epidemiology

Japan Epidemiology

Current Graft Versus Host Disease (GvHD) Treatment and Medical Practices

Unmet needs

Graft Versus Host Disease (GvHD) Marketed Drugs

Graft Versus Host Disease (GvHD) Emerging Drugs

Graft Versus Host Disease (GvHD) 7MM Market Analysis

United States

EU-5 countries: Market Outlook

Japan Market Outlook

Graft Versus Host Disease (GvHD) Market Drivers

Graft Versus Host Disease (GvHD) Market Barriers

SWOT Analysis

Reimbursement and market access

Appendix

DelveInsight Capabilities

Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

[speedylightheart]

Stem Cell Therapy Market Size, Share & Trends Analysis Report By Product Forecast To 2025

Stem Cell Therapy Market is valued at USD 9.32 Billion in 2018 and expected to reach USD 16.51 Billion by 2025 with the CAGR of 8.5% over the forecast period.

Rising prevalence of chronic diseases, increasing spend on research & development and increasing collaboration between industry and academia driving the growth of stem cell therapy market.

Scope of Stem Cell Therapy Market-

Stem cells therapy also known as regenerative medicine therapy, stem-cell therapy is the use of stem cells to prevent or treat the condition or disease. Stem cell are the special type of cells those differentiated from other type of cell into two defining characteristics including the ability to differentiate into a specialized adult cell type and perpetual self-renewal. Under the appropriate conditions in the body or a laboratory stem cells are capable to build every tissue called daughter cells in the human body; hence these cells have great potential for future therapeutic uses in tissue regeneration and repair. Among stem cell pluripotent are the type of cell that can become any cell in the adult body, and multipotent type of cell are restricted to becoming a more limited population of cells.

The stem cell therapy has been used to treat people with conditions including leukemia and lymphoma, however this is the only form of stem-cell therapy which is widely practiced. Prochymal are another stem-cell therapy was conditionally approved in Canada in 2012 for the treatment of acute graft-vs-host disease in children those are not responding to steroids. Nevertheless, hematopoietic stem cell transplantation is the only established therapy using stem cells. This therapy involves the bone marrow transplantation.

Stem cell therapy market report is segmented based on type, therapeutic application, cell source and by regional & country level. Based upon type, stem cell therapy market is classified into allogeneic stem cell therapy market and autologous market.

Based upon therapeutic application, stem cell therapy market is classified into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases and other applications. Based upon cell source, stem cell therapy market is classified into adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, cord blood/embryonic stem cells and other cell sources

The regions covered in this stem cell therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of stem cell therapy is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Stem Cell Therapy Companies:

Stem cell therapy market report covers prominent players like,

Osiris Therapeutics, Inc

MEDIPOST

Anterogen, Ltd.

Cynata

Pharmicell

Cytori Therapeutics

Holostem Terapie Avanzate S.r.l.

JCR Pharmaceuticals

NuVasive

RTI Surgical

STEMCELL Technologies

BIOTIME

Osiris Therapeutics

Human Longevity

Advanced Cell Technology

Promethera Biosciences

Mesoblast and AlloSource

others

Stem Cell Therapy Market Dynamics –

Rising spend on research and development activities in the research institutes and biotech industries driving the growth of the stem cell therapy market during the forecast period. For instance, in January 2010, U. S. based Augusta University initiated Phase I clinical trial to evaluate the safety and effectiveness of a single, autologous cord blood stem infusion for treatment of cerebral palsy in children. The study is estimated to complete in July 2020. Additionally, increasing prevalence of chronic diseases creating the demand of stem cell therapy. For instance, as per the international diabetes federation, in 2019, around 463 million population across the world were living with diabetes; by 2045 it is expected to rise around 700 million. Among all 79% of population with diabetes were living in low- and middle-income countries. These all factors are fuelling the growth of market over the forecast period. On the other flip, probabilities of getting success is less in the therapeutics by stem cell may restrain the growth of market. Nevertheless, Advancement of technologies and government initiative to encourage research in stem cell therapy expected to create lucrative opportunity in stem cell therapy market over the forecast period.

Stem Cell Therapy Market Regional Analysis –

North America is dominating the stem cell therapy market due increasing adoption rate of novel stem cell therapies fueling the growth of market in the region. Additionally, favorable government initiatives have encouraging the regional market growth. For instance, government of Canada has initiated Strategic Innovation Fund Program, in which gov will invests in research activities carried out for stem cell therapies. In addition, good reimbursing scheme in the region helping patient to spend more on health. Above mentioned factors are expected to drive the North America over the forecast period.

Asia Pacific is anticipated to grow at a highest CAGR over forecast period due to rising awareness of benefits of stem cell therapies among the population. In addition, increasing collaboration between industry-academia to initiate research and development in the stem cell therapy expected to create the huge growth over the forecast period. For instance, as per the report of Pharma Focus Asia, members of Asia-Pacific Economic Cooperation collaborated with Life Sciences Innovation Forum to involve professionals having expertise in stem cell therapies from academia and research centers to promote developments in stem cell research which will foster regional market growth.

Key Benefits for Stem Cell Therapy Market Reports –

Global Market report covers in depth historical and forecast analysis.

Global Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global Market report helps to identify opportunities in market place.

Global Market report covers extensive analysis of emerging trends and competitive landscape.

Stem Cell Therapy Market Segmentation –

By Type

Allogeneic Stem Cell Therapy Market, By Application

Musculoskeletal Disorders

Wounds and Injuries

Surgeries

Acute Graft-Versus-Host Disease (AGVHD)

Other Applications

Autologous Market, By Application

Wounds and Injuries

Cardiovascular Diseases

Gastrointestinal Diseases

Other Applications

By Therapeutic Application

Musculoskeletal Disorders

Wounds and Injuries

Cardiovascular Diseases

Surgeries

Gastrointestinal Diseases

Other Applications

By Cell Source

Adipose Tissue-Derived Mesenchymal Stem Cells

Bone Marrow-Derived Mesenchymal Stem Cells

Cord Blood/Embryonic Stem Cells

Other Cell Sources

Regional & Country Analysis North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

About Us:

Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at sales@industrystatsreport.com

[databrigemarketresearchreports]

Graft-Versus-Host Disease (GVHD) Market Current Status by Major Key vendors and Trends by Forecast to 2029

Graft-Versus-Host Disease (GVHD) business report is a well-generated market report which helps achieve comprehensive analysis of the market structure along with estimations of the various segments and sub-segments of the Graft-Versus-Host Disease (GVHD) market. This report deals with plentiful aspects of the DBMR industry. The CAGR values covered here estimates the fluctuation about the rise or fall of demand for the specific forecasted period with respect to investment. A comprehensive market study and analysis of trends in consumer and supply chain dynamics underlined in this report assists businesses in drawing the strategies about sales, marketing, advertising, and promotion. Rising cases of cancer coupled with rising demand for bone marrow transplants are attributable to the growth of graft-versus-host disease (GFHD) market. Data Bridge Market Research analyses that the graft-versus-host disease (GFHD) will exhibit a CAGR of around 7.0% for the forecast period of 2021-2028.

Ask for Sample Report at https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-graft-versus-host-disease-gvhd-market

Some of the market players studied in this report are:

Merck & Co., Inc., Sanofi, Novartis AG, Astellas Pharma Inc. Neovii Pharmaceuticals AG, Soligenix, Mesoblast Ltd, Johnson & Johnson Services, Inc., Mallinckrodt., ElsaLys Biotech SA, Incyte., Kiadis Pharma, Pfizer Inc., Genzyme Corporation., Abbott, Eli Lilly And Company

The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market.

On     the basis of treatment type, the graft-versus-host disease (GFHD) market     is segmented into prophylaxis GVHD, chronic GVHD and acute GVHD.

On     the basis of end user, the graft-versus-host disease (GFHD) market is     segmented into hospital pharmacies, retail pharmacies and online     pharmacies.

Speak to Analyst https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-graft-versus-host-disease-gvhd-market

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Graft-Versus-Host Disease (GVHD) market.

Product Development/Innovation: Detailed insights on the upcoming technologies, RD activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Global Graft-Versus-Host Disease (GVHD) market.

Why should buy this report?

1.       Provides in depth research analysis of the overall Graft-Versus-Host Disease (GVHD) market. which can help save time for start-up businesses related to the Graft-Versus-Host Disease (GVHD) Market.

2.       The Graft-Versus-Host Disease (GVHD) markets latest news, forecast analysis as well as the key competitors of the market are easily available with all the necessary information.

3.       The Graft-Versus-Host Disease (GVHD) report comprises of graphs, pie charts and other representations that can help the reader understand the information at a glance.

4.       Through the Graft-Versus-Host Disease (GVHD) report the manufacturers can understand the consumer behaviour, business segments as well as sell products-based information provided.

Request for Customization https://www.databridgemarketresearch.com/customization/global-graft-versus-host-disease-gvhd-market

Thank you for reading our report. For further inquiry, please get in touch with us. Our team will ensure the report is customized to meet your requirements.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818 Email: Sopan.gedam@databridgemarketresearch.com 

[mrunalnerkarblog]

During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients

[bhandvalkar94]

Latest Industry News: Global Oncology Drugs Market Research Report 2022-2030

The new statistical report titled as Oncology Drugs Market has recently published by Absolute Markets Insights. This study comprises mix data containing the recent trends, technological platforms, tools, and certain methodologies. It gives an overview of the market dynamics such as the changing needs of the clients in different regions. This research report offers a comprehensive analysis of different parameters of businesses like profit margin, shares and pricing structures. It has been compiled by using qualitative and quantitative analysis techniques. The valuable insights of businesses have been examined by using primary and secondary research methodologies in a particular manner.

A section containing the data about different factors influencing the progress of the Oncology Drugs market. This research report offers a bird’s eye view on the historical as well as current trends operating in the global Oncology Drugs market. Different market segment and its sub-segment have been elaborated to understand the market clearly. Leading key players have been profiled to get detailed data about company profiles, contact details, and revenue of the companies.

Top Key Players includes: F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca, Merck & Co., Inc.,CELGENE CORPORATION and Polaris Pharmaceuticals amongst others

For More Information Click@ https://www.absolutemarketsinsights.com/reports/Oncology-Drugs-Market-2019-2027-273

In terms of revenue, global oncology drugs market was valued at US$ 119 billion in 2020. The introduction and approval of anti-PD-1 agents’ nivolumab and pembrolizumab for NSCLC has bought a new era for the cancer industry. The number of patients receiving single-agent chemotherapy decreased considerably in the recent past and the patients who received EGFR-TKI based therapy also reduced substantially

Single drug therapies coupled with monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have shown little efficacy in patients suffering from metastatic breast cancer. The same is low number of tumour-infiltrating lymphocytes, found in most of the breast cancers. As a result, the development of combinations of molecularly targeted therapies and immunotherapy have proven to be a great success.

The China and United States hold the leading positions in the cancer cell therapy pipeline. The number for the same are 439 and 305 agents respectively. Majority of the drugs developed in the United States are at pre-clinical stage, whereas the drugs that are being developed in China are at clinical stages

In August, 2019, the U.S. FDA granted approval to Rozlytrek. This drug is for adoslescents and adult who are suffering from genetic cancer defects. This drug got approval for treating diseases like NTRK (neurotrophic tyrosine receptor kinase) gene fusion. The drug has a unique ability to shrink tumors and has been evaluated in four clinical trials, studying the adults who are suffering from NTRK fusion-positive tumors.

Oncology Drugs Market Segmentation:

By Indication

Breast     Cancer

Prostate     Cancer

Basal     Cell Cancer

Skin     Cancer (Non-Melanoma)

Colorectal     cancer

Lung     Cancer

Renal     Cancer

Bladder     Cancer

Lymphoma

Others

By Treatment

  DNA-Repair       Enzyme Inhibitors

  Histone       Deacetylase Inhibitors

  Janus-Associated       Kinase (JAK) Inhibitors

  Phosphoinositide       3-kinase inhibitors (PI3K inhibitors)

  Proteasome       Inhibitors

  Tyrosine       Kinase Inhibitors

  PD-1       and PD-L1 inhibitors

  Others

   Open      Surgery

 Minimally      Invasive Surgery

 Chimeric      antigen receptor (CAR) T-cell therapy

 Cytokine      Treatment

 Donor      lymphocyte infusion

 Monoclonal      Antibody Treatment

 Others

 Autologous      stem cell transplantation

 Allogeneic      stem cell transplantation

 Reduced-Intensity      Allogeneic Stem Cell Transplantation

 Graft-Versus-Host      Disease

 By Region

North     America

Europe

Asia     Pacific

Middle     East and Africa

Latin     America

Why Buy this Report?

·         Extensive analysis on latest trends and growth opportunities in different regions across the globe

·         Comprehensive assessment on recent technological advancements and forecast of the upcoming period

·         A comparative analysis of leading players and emerging players in the Oncology Drugs market

·         Authentic information on new product launches, organic and inorganic strategies, and more

·         Valuable insights on the impact of regulatory framework on the global Oncology Drugs market

Contact Us:

Contact Name: Shreyas Tanna

Company: Absolute Markets Insights

Email Id: sales@absolutemarketsinsights.com

Phone: IN +91-7400-24-24-24, US +1-510-420-1213

Website: www.absolutemarketsinsights.com

[deshpandeisha]

Chronic Graft versus Host Disease Market Future Trends, Growth Factors, Strategy, Price

The global Chronic Graft-versus-Host Disease (cGvHD) market size reached USD 3.5 Billion in 2021 and is expected to register a revenue CAGR of 13.3% during the forecast period, according to the latest analysis by Emergen Research. Increasing number of allogenic transplants such as bone marrow transplants, rising regulatory approvals for the treatment of Graft Versus Host Disease (GvHD) as well as increase in prevalence of nephrological leukemia, myeloma, and other forms of cancer are some of the key factors driving revenue growth of the chronic graft-versus-host disease market.

The report focuses on current and future market growth, technological advancements, volume, raw materials, and profiles of the key companies involved in the market. The report provides valuable insights to the stakeholders, investors, product managers, marketing executives, and other industry professionals.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1640

Competitive Terrain:

The global Chronic Graft versus Host Disease industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Merck KGaA, Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc., F. Hoffman-La Roche Ltd, Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, and Takeda Pharmaceutical Company Limited

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Chronic Graft versus Host Disease market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Chronic Graft versus Host Disease market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Chronic Graft versus Host Disease market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1640

Market Segmentations of the Chronic Graft versus Host Disease Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Chronic Graft versus Host Disease market on the basis of product, application, and region:

Segments Covered in this report are:

Treatment Type Outlook (Revenue, USD Billion; 2019-2030)

Corticosteroids

mTOR inhibitors

Tyrosine Kinase Inhibitors (TKIs)

Monoclonal Antibodies

Photopheresis light treatment (ECP)

Others

Distribution Channel Outlook (Revenue, USD Billion; 2019-2030)

Hospitals Pharmacies

Retail Pharmacies

Online Pharmacies

Regional Outlook (Revenue, USD Billion; 2019-2030)

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

U.A.E.

South Africa

Turkey

Rest of MEA

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/chronic-graft-versus-host-disease-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1640

[automationandinstrumentation]

HLA Typing for Transplant Market Size Forecast to Reach $ 879.91 Million by 2025

HLA Typing for Transplant Market size is forecast to reach $ 879.91 Million by 2025, growing at a CAGR of 6.2% during the forecast period 2020-2025. Human leukocyte antigen (HLA) typing is used to match patients and donors for bone marrow or cord blood transplants. HLA are proteins or rather, markers found on most cells in the body. Our immune system uses these markers to recognize which cells belong in the body and which does not. The histocompatibility complex gene group provides instructions for making a group of HLA. In children, compared to the use of HLA mismatched units, the use of HLA-matched units is associated with a lower risk of acute Graft versus host disease (GVHD) and mortality, while in adults HLA mismatches may have a lower impact on outcome. Growing public-private funding for target research activities, the growing burden of infectious diseases, the growing number of transplant procedures, and technological advancements in the field of transplant diagnostics are driving the market growth in recent years. In addition, major market development of key players like Genome Diagnostics and Illumina are additional factors driving the growth of the market.

Technology - Segment Analysis

Molecular Assays held the largest share in the product segment of HLA Typing for Transplant Market in 2019, and are estimated to grow at a CAGR of 6.8% during the forecast period 2020-2025. Molecular diagnostics is a more sensitive method allowing detection of lower amounts of infectious agents and therefore giving the ability to detect infections earlier than was previously possible. This ability is especially significant in blood screening. It is estimated that molecular assays will continue to be the fastest growing segment and will register the highest CAGR during the forecast period 2020-2025. Many in-house and commercial assays that detect the COVID-19 virus have been developed or are currently under development. Many of these molecular assays are currently being validated in partner laboratories.

Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=16814

Report Price: $ 4500 (Single User License)

End Use - Segment Analysis

Academic and research institutes held the major share in the end use segment of HLA Typing for Transplant Market in 2019. Rapid modernization and automation of diagnostic laboratories, along with growing number of research & development activities outsourced by pharmaceutical & biotechnology companies to independent reference laboratories are driving the demand of this segment. This has led to considerable increase in market growth of the segment in recent years. Hospital is forecast to grow at the fastest rate with the highest CAGR during the forecast period 2020-2025, owing to increasing purchasing power for basic amenities of the market.

Geography - Segment Analysis

North America dominated the geography segment of HLA Typing for Transplant Market with a share of more than 38.24% in 2019, followed by Europe. Presence of a highly developed healthcare infrastructure, high adoption of innovative transplant diagnostic technologies (including HLA typing) among medical professionals and a large number of organ transplantation procedures performed in the region are helping in significant market growth in the region. Europe held the second place in the geography segment share of the market. In Europe, rise in launch of products and catalogue provides new insights into European population genetics and will be a very useful tool for tissue-typing laboratories in urban areas of Europe.

Asia-Pacific is estimated to grow at the fastest rate at a higher CAGR during the forecast period 2020-2025. This is owing to increasing awareness levels owing to government and non-government organizations’ efforts for educating the masses about the need and importance of organ donations.

Drivers – HLA Typing for Transplant Market

Growing public-private funding for target research activities

New market grants and relaxed government policies are giving way to increased funding’s and research activities. Such processes, which are run by government, corporations or foundations, allocate scarce funds. Independent research activity are increasing, which can lead to growth of knowledge/process in an area, which can grow into a major project. This is set to drive the market growth in the forecast years 2020-2025.

Growing number of transplant procedures

Increasing number of organ transplant procedures as well as repetitive purchase of immunosuppressant’s are anticipated to boost the segment growth. Demand for transplants among the growing number of people who need this lifesaving procedure is increasing. This is set to help in market growth during the forecast period 2020-2025.

Talk to one of our sales representative about the full report by providing your details in the link below:

https://www.industryarc.com/support.php?id=16814

Challenges – HLA Typing for Transplant Market

High costs associated with molecular HLA typing

The cost of HLA typing DNA test in the medical sector varies within the higher ranges depending on various conditions, like no. of alleles screened, quality of data high resolution or low resolution and the technology used. Typing costs vary widely, with SST being the least expensive and RT-PCR/NGS being the most expensive techniques. Thus, it is anticipated to hamper the market growth during the forecast period 2020-2025.

HLA Typing for Transplant Industry Outlook

Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the HLA Typing for Transplant Market. In 2019, the top players present in the market consolidate HLA Typing for Transplant Market share. HLA Typing for Transplant Market top 10 companies are Thermo Fisher Scientific, Inc., Genome Diagnostics, Illumina, CareDx, Inc., Immucor, Inc., Bio-Rad Laboratories, Inc., F. Hoffman-La Roche Ltd., Hologic, Inc., Luminex, Takara Bio and Omixon among others.

Acquisitions/Product Launches

In May 2019, Genome Diagnostics B.V. announced that Ampersand Capital Partners has completed a minority, growth equity investment in the company.

In March 2015, Illumina announced the launch of TruSight HLA, an end-to-end solution that produces a comprehensive view of the HLA region by sequencing 11 HLA genes for accurate HLA typing across thousands of known and novel HLA alleles.

Key Takeaways

North America dominated the HLA Typing for Transplant Market in the year 2019 owing to presence of a highly developed healthcare infrastructure, high adoption of innovative transplant diagnostic technologies (including HLA typing) among medical professionals and a large number of organ transplantation procedures performed in the region. The HLA Typing for Transplant Market scope for different regions will be provided in the final report.

Growing public-private funding for target research activities, the growing burden of infectious diseases, the growing number of transplant procedures, and technological advancements in the field of transplant diagnostics is estimated to drive the industry growth during the forecast period 2020-2025.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the HLA Typing for Transplant Market report.

High costs associated with molecular HLA typing for transplant tests is anticipated to hamper the market growth of the HLA Typing for Transplant Industry.

Related Reports :

A. Tissue Banking Market

https://www.industryarc.com/Report/237/tissue-banking-market-research-analysis-report.html

B. Serological Transplant Diagnostics Market

https://www.industryarc.com/Research/Serological-Transplant-Diagnostics-Market-Research-501753

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

[lucy20kart]

The Demand For Covid-19 Vaccines And Treatment Drugs, The Pharmaceutical And Biotechnology Industries Are Expected To Grow Significantly This, In Turn, Is Expected To Have A Significant Impact On The Market For Graft Versus Host Disease.

The Graft Versus Host Disease (Gvhd) Market is divided into three categories: product type, treatment type, and end user. The growth of these segments will assist you in analysing meagre growth segments in the industries, as well as providing users with valuable market overview and market insights to assist them in making strategic decisions for identification of core market applications. The global graft versus host disease treatment market is also influenced by bone marrow transplant surgeries performed worldwide for specific types of cancer. The increase in allogeneic stem cell transplants is expected to boost the market for graft versus host disease treatment. However, costs associated with GvHD treatment authorization and clinical trials are expected to restrain the global graft versus host disease (GvHD) treatment market.

Read More@ https://bit.ly/3mKMRw6

[myabhijitr]

Graft Versus Host Disease (GvHD) Market – High investment in research and development is expected to favor growth of the market

Overview:

Graft versus host disease (GvHD) is a condition that might occur after an allogeneic transplant. A condition that occurs when donor bone marrow or stem cells attack the recipient. Gvhd occur especially in immune-compromised patients. Radioactive agents or chemicals affect both the cancer cells and healthy cells during cancer treatment. The reconstruction of affected body cells can be done using stem cells and bone marrow transplant. The bone marrow is obtained from the donor through an infusion after a high dose of chemotherapy, which in turn help to resume the production of blood cells. GvHD occurs when certain white blood cells are not compatible with the existing cell type and, thus, the recipient’s body is attacked by the transplanted cells. The signs and symptoms of graft versus host disease are usually not too severe, although in some cases it can be fatal. Thus, cells of both the recipient and donor are closely screened and matched prior to the transplant to avoid the risk of Gvhd.

Ask for free Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/184

Drivers:

Increasing research and development (R&D) activities is expected to boost the growth of the global graft versus host disease (GvHD) market over the forecast period. The graft versus host disease (GvHD) market has evolved significantly in recent times with the introduction of small molecule immunosuppressant therapies (biological and patented). Moreover, the current R&D programs/activities are equipped with novel therapies such as Adienne Pharma’s Begedina and mesenchymal stem cell therapies. These programs/activities are characterized by an increasing trend towards maintaining an appropriate prophylactic regimen and inhibiting activation and proliferation of T-cell. Such regimens are used for hematopoietic stem cell transplantation and are tailored to the conditioning and transplant types. However, there is a great potential for risk of opportunistic infection during this process.

However, most R&D strategies/activities, including clinical studies regarding targeting niche subgroup under GvHD, such as steroid refractory cGVHD and aGVHD, are the major R&D strategies in the GVHD pipeline. Extensive R&D activities are expected to drive growth of the global graft versus host disease market during the forecast period.

Moreover, rise in need for GvHD management is also expected to aid in the global graft versus host disease market growth. There are currently few or no guidelines for GvHD management that can accurately maintain data from large populations suffering from GvHD, although some recommendations exist for such treatments.

Furthermore, graft versus host disease is orphan in nature, which may be one of the important factors influencing the treatment regimes and lack of guidelines. Lack of randomized clinical trials and non-popularity of Gvhd is another factor that is expected to hamper the growth of the market. This in turn has resulted in inappropriate clinical evidence, which are not comparable and not applicable to all GvHD patients. However, advancements in early detection process is expected to propel the global graft versus host disease market growth.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐎 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐓𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏

Buy This Complete Business Report @  https://www.coherentmarketinsights.com/insight/buy-now/184

Market players are engaged in R&D to enhance the outcomes of the therapy, which in turn is also expected to aid in the growth of the market. For instance, in 2017, an international research team led by the University of Michigan Life Sciences Institute revised the understanding of the key cellular and molecular events that trigger GvHD.

Moreover, market players are focusing on launching novel products, as well as are adopting various strategies, such as merger and acquisition, to gain competitive edge in the market and to strengthen their product portfolio. For instance, in February 2017, Kalytera Therapeutics, Inc. announced that it has completed the previously announced acquisition of Talent Biotechs Ltd. to strengthen its position as an emerging market leader in cannabidiol pharmaceuticals.

Competitive Landscape:

Key players operating in the global graft versus host disease market are Novartis AG, Sanofi, Merck & Co., Astellas Pharma, Mesoblast Ltd., Soligenix, Inc., and Neovii Biotech GmbH, among others.

Key Developments:

In May 2019, the Food and Drug Administration (FDA) approved ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory GvHD in adult and pediatric patients 12 years and older.

In November 2017, Merck & Co., Inc., received FDA approval for PREVYMIS (letermovir), once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for the patients suffering from GvHD.

In August 2017, Pharmacyclics LLC received FDA approval for Imbruvica (ibrutinib) drug, for the treatment of adult patients with chronic GvHD.

[abdulnadeem5150]

Graft versus host disease (Gvhd) is a mild to severe complication that can develop with any stem cell or bone marrow transplant. It is more common in immune-compromised patients. Radioactive agents or chemicals used in cancer treatment can harm healthy cells as well as malignant cells.Read more,

[bitchyphilosopherprince]

Global Autoimmune Partnering 2014-2021: Deal trends, players and financials

Bharat Book Bureau Provides the Trending Market Research Report on “Global Autoimmune Partnering 2014-2021: Deal trends, players and financials” under  Life Sciences Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.

Global Autoimmune Partnering 2014 to 2021 provides the full collection of Autoimmune disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.

Trends in Autoimmune partnering deals Financial deal terms for headline, upfront and royalty by stage of development Autoimmune partnering agreement structure Autoimmune partnering contract documents Top Autoimmune deals by value Most active Autoimmune dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

The report includes coverage of the following autoimmune diseases:

Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison’s disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Cronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.

The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Autoimmune deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Autoimmune deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2014. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Browse our full report with Table of Content : https://www.bharatbook.com/report/897788/global-autoimmune-partnering-deal-trends-players-and-financials

About Bharat Book Bureau: Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors

Contact us at: Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Email: poonam@bharatbook.com Website: www.bharatbook.com

[healtcare]

Global Haematology and Flow Cytometry Market

Global Haematology and Flow Cytometry Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.

Global Haematology and Flow Cytometry Market Dynamics:

Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells. Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives. ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth. The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays. Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years. To know about the Research Methodology :- Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period. This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.